For biologics CMC and antibody engineering
Which of these numbers can travel to another lab?
A sequence goes in. A protocol-stamped report comes out: the measured cross-lab verdict for each assay, the sequence liabilities, and the clinical non-finding. Abx does not invent an aggregate developability score, and it does not predict immunogenicity.
- Portable
- HIC ρ 0.968, SMAC ρ 0.923, HAC ρ 0.919. AC-SINS pH 7.4 ρ 0.890, with caution.
- Does not travel
- Tm2 ρ −0.061 (n=104). Titer ρ 0.325 (n=129). Do not compare those numbers across sites.
- Not a prediction
- Polyreactivity joined to clinical %ADA gave AUC 0.356. The interval includes chance. That result stays a non-finding.
Build a stamped report
Three worked examples are loaded locally. Nothing is sent until you ask for the stamp. Customer sequences belong on a private site licence, not on this public desk.
What the check is for
One site. One annual licence. About $100,000.
The buyer is a VP or Head of Biologics CMC, or a VP of Antibody Engineering, at a mid-size biotech, a biosimilar developer, or a biologics CDMO. The economic argument is one avoided non-portable Tm decision, or one clone the panel should not have advanced, inside a campaign that already costs millions.
List price for the private desk is USD 100,000 per year for one development site: the stamped report, the calibration tables, three programme reviews, and a private deployment so candidate sequences stay off this public page. A paid pilot can come first. This page does not take a card.